F-star Therapeutics Shares Up 9% Premarket After Janssen Biotech Deal
October 20 2021 - 8:58AM
Dow Jones News
By Chris Wack
F-star Therapeutics Ltd. shares were up 9% to $6.96 in premarket
trading Wednesday after the biopharmaceutical company said it
entered into a license and collaboration agreement with Johnson
& Johnson's Janssen Biotech Inc.
Under the terms of the agreement, F-star said it will grant
Janssen a worldwide, exclusive royalty-bearing license to research,
develop, and commercialize up to five novel bispecific antibodies
directed to Janssen therapeutic targets using F-star's proprietary
Fcab and mAb platforms.
Janssen will be responsible for all research, development, and
commercialization activities under the agreement.
F-star said it is entitled to receive upfront fees of $17.5
million, and near-term fees and potential further milestones of up
to $1.35 billion. F-star is also eligible to receive potential
tiered mid-single digit royalties on annual net sales.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 20, 2021 08:43 ET (12:43 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jul 2023 to Jul 2024